ZNF423: A New Player in Estrogen Receptor-Positive Breast Cancer

ZNF423: A New Player in Estrogen Receptor-Positive Breast Cancer

Preventive therapy can target hormone-responsive breast cancer (BC) by treatment with selective estrogen receptor modulators (SERMs) and reduce the incidence of BC. Genome-wide association studies have identified single nucleotide polymorphisms (SNPs) with relevant predictive values, SNPs in the ZNF...

Full description

Bibliographic Details
Main Authors: Heather M. Bond, Stefania Scicchitano, Emanuela Chiarella, Nicola Amodio, Valeria Lucchino, Annamaria Aloisio, Ylenia Montalcini, Maria Mesuraca, Giovanni Morrone
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-05-01
Series:Frontiers in Endocrinology
Subjects:
breast cancer
cathepsin O
calmodulin like 3
estrogen receptors
single nucleotide polymorphisms
selective estrogen receptor modulators
Online Access:https://www.frontiersin.org/article/10.3389/fendo.2018.00255/full

Internet

https://www.frontiersin.org/article/10.3389/fendo.2018.00255/full

Similar Items